Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Incyte Corporation (INCY)

-NasdaqGS
44.54 Up 0.56(1.27%) Apr 17, 4:00PM EDT
|After Hours : 44.54 0.00 (0.00%) Apr 17, 4:29PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Incyte Corporation
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States - Map
Phone: 302-498-6700
Website: http://www.incyte.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:481

Business Summary 

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; in Phase II trial for pancreatic cancer; and in Phase I trial for the treatment of malignancies, as well as baricitinib, a JAK inhibitor, which is in Phase III trial for rheumatoid arthritis, in Phase IIb trial for psoriasis, and in Phase II trial for diabetic nephropathy. The company’s products in pipeline also comprise INC280, which is in Phase II clinical trial for the treatment of solid tumors, hepatocellular carcinoma, and non-small cell lung cancer; and INCB24360 that is in Phase II clinical trial for the treatment of metastatic melanoma and ovarian cancer; INCB40093 and INCB39110+INCB40093, which are Phase I clinical trial products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I clinical trial products for the treatment of rheumatoid arthritis. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc., as well as strategic collaboration arrangement with Merck. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Key Statistics


Company Websites 
Home Page
Products & Services
Subsidiaries
Search Yahoo! for:
More on Incyte Corporation

Corporate Governance 
Incyte Corporation’s ISS Governance QuickScore as of Apr 1, 2014 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Roy A. Whitfield , 60
Co-Founder and Director
N/AN/A
Mr. David C. Hastings CPA, 52
Chief Financial Officer and Exec. VP
568.00K0.00
Ms. Paula J. Swain , 56
Exec. VP of HR
556.00K2.16M
Dr. Richard S. Levy M.D., 56
Chief Drug Devel. & Medical Officer and Exec. VP
573.00K425.00K
Mr. James M. Daly , 52
Chief Commercial Officer and Exec. VP
245.00K0.00
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders